Hints and tips:
...As well as proceeds from its Covid products, Pfizer has also benefited from the spin-off of its Upjohn generics business, which combined with Mylan to form Viatris in late 2020....
...In 2020, Pfizer spun off its generics business Upjohn, combining it with Mylan to form Viatris, while Johnson & Johnson, GSK, Pfizer and Novartis have all shed their consumer health businesses selling over-the-counter...
...Gilead told the FT that in India the price of the drug and the terms of supply are negotiated by the US company Viatris, previously also known as Mylan, which holds the marketing authorisation for AmBisome...
...Results and forecasts exclude its Upjohn unit, as Pfizer closed the transaction to merge the generics business with Mylan during the quarter....
...Mylan, which makes a generic version of Truvada, pays royalties for some its sales to the CDC. When the generic market forms in the US, it said, it will continue to do so....
...Mylan, a US-based generics maker, has restarted production of hydroxychloroquine at its West Virginia plant and is looking to increase manufacturing outside of the US too....
...In mid-afternoon trading in New York, shares in Mylan, which is in the process of merging with Pfizer’s generics business Upjohn, were up 2.6 per cent to $22.83....
...Teva, Mylan and others in the lawsuits have denied wrongdoing....
...The deal with Mylan is similar. Here, however, Pfizer is spinning off Upjohn and then combining it with all of Mylan....
...The plans would also see Mylan’s chief executive Heather Bresch depart, after leading the company for seven years....
...The deal comes after a near-50 per cent drop in Mylan shares over the past year as sales slowed. Heather Bresch will retire after eight years as Mylan chief executive when the transaction closes....
...and spinning off their consumer health divisions, which sell over-the-counter products, while Pfizer is in the process of trying to combine its generics business Upjohn with the large generics drugmaker Mylan...
...agreed in the pharmaceutical and healthcare sector, according to Refinitiv, including AbbVie’s decision to buy the maker of Botox, Allergan, for $63bn; Pfizer’s sale of its off-patent drug business to Mylan...
...Rivals entering the market include Amgen, Sandoz, Biogen, Samsung Bioepis and Mylan. In the first quarter, Humira represented 56 per cent of revenue at $4.4bn....
...Third, Mylan has exploited its dominant-supplier position....
...So far, Mylan, Teva, Sandoz, and Amneal have issued press releases discussing plans to build significant amounts of inventory of hydroxychloroquine for treatment of COVID-19....
...Rajiv Malik, president of Mylan, suggested that quality and continuity of supply, not simply price, must be a factor in payers’ commissioning decisions....
...The shortage of EpiPens is particularly irksome for Mylan as it tries to move on from controversy over the cost of the medicine....
...Amgen, Sandoz, Mylan, and Samsung Bioepis launched copycat drugs in Europe two weeks ago. Prices differ between markets but are between 10 and 80 per cent cheaper....
...The companies now under investigation are: Heritage Pharmaceuticals, Inc.; Aurobindo Pharma USA, Inc.; Citron Pharma, LLC; Mayne Pharma (USA), Inc.; Mylan Pharmaceuticals, Inc.; Teva Pharmaceuticals USA;...
...Last week, Revance announced it was teaming up with Mylan , the world’s largest generic drugmaker by market value, to develop the biosimilar product, prompting a sell-off in Allergan’s shares....
...Chrys Kokino, global biologics head for US drugmaker Mylan, which has seen prices for its generic drugs squeezed in recent years, said his own company was “very heavily invested [in] and committed to the...
...Paulson & Co’s biggest public holdings, according to regulatory filings, are pharma companies Mylan, Shire, Valeant and Allergan, as well as an exchange-traded fund that tracks the price of gold....
...The Texas judge said the intellectual property was invalid, opening the way for generic competitors Mylan and Teva to market a cheaper copycat version of the prescription eye drop Restasis....
...October struck down a patent protecting its second-best seller, Restasis — a prescription eye drop, which generated roughly $1.5bn in sales for Allergan in 2016 — and flung open the doors to competitors like Mylan...
International Edition